Vita Life SciencesASX:VLS 94 EBITDA Margin % is 16.35% as of Dec. 2025, which is 3% below its 10-year median of 16.93. GuruFocus rates ASX:VLS with a GF Score™ of 94/100 and a GF Value™ of A$2.47 (Fairly Valued). The stock has 1 warning sign investors should review. Among 955 Drug Manufacturers companies, Vita Life Sciences ranks better than 58.43% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Vita Life Sciences's EBITDA for the
six
months ended in Dec. 2025 was A$7.80 Mil. Vita Life Sciences's Revenue for the
six
months ended in Dec. 2025 was A$47.73 Mil. Therefore, Vita Life Sciences's EBITDA margin for the quarter that ended in Dec. 2025 was 16.35%.
Vita Life Sciences (ASX:VLS) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Vita Life Sciences EBITDA Margin % Related Terms
Vita Life Sciences EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Vita Life Sciences's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vita Life Sciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vita Life Sciences EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vita Life Sciences's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Vita Life Sciences's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vita Life Sciences (ASX:VLS) has a EBITDA Margin % of 16.35% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Vita Life Sciences and its competitors. This is near median its historical median of 16.93. Over the past decade, Vita Life Sciences' EBITDA Margin % has ranged from 11.82 to 20.51. According to the industry distribution chart, Vita Life Sciences ranks #397 out of 955 companies in the Drug Manufacturers industry, placing it in the top 41.6%.
Is Vita Life Sciences' EBITDA Margin % too high?
Vita Life Sciences' current EBITDA Margin % of 16.35% is near median its 10-year median of 16.93. Over the past 10 years, this metric has ranged from a low of 11.82 to a high of 20.51. The Drug Manufacturers industry median EBITDA Margin % is 12.39. Vita Life Sciences' value of 16.35% is 32% above this industry median. Based on the distribution chart, Vita Life Sciences ranks #397 out of 955 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Vita Life Sciences has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vita Life Sciences' EBITDA Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vita Life Sciences ranks #397 out of 955 companies for EBITDA Margin %. This puts Vita Life Sciences in the upper half of its industry. The industry median EBITDA Margin % is 12.39. Vita Life Sciences' value of 16.35% is 32% above this benchmark. Historically, Vita Life Sciences' own EBITDA Margin % has ranged from 11.82 to 20.51 over the past decade. While the company's 10-year median is 16.93 vs. the industry median of 12.39, Vita Life Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.39, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vita Life Sciences's current EBITDA Margin % of 16.35% is 32% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Vita Life Sciences and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.39 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vita Life Sciences's current EBITDA Margin % is 16.35%, which is near median its own 10-year median of 16.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vita Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Vita Life Sciences (ASX:VLS) is currently considered Fairly Valued. The stock's GF Value™ is A$2.47, compared to a current price of A$2.50 — trading 1.2% above its estimated fair value. The current EBITDA Margin % is 16.35%, which is near median its 10-year median of 16.93 and 32% above the Drug Manufacturers industry median of 12.39. Vita Life Sciences' overall GF Score™ is 94/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Vita Life Sciences (ASX:VLS), the current EBITDA Margin % is 16.35% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vita Life Sciences (ASX:VLS) Overvalued in 2026?
Based on GuruFocus' analysis, Vita Life Sciences stock appears to be overvalued.
The current stock price of A$2.50 is trading 1.2% above its estimated GF Value™ of A$2.47.
GuruFocus considers Vita Life Sciences to be Fairly Valued.
Key valuation signals for ASX:VLS:
EBITDA Margin %: 16.35% (near median its 10-year median of 16.93)
GF Value™: A$2.47 vs. price of A$2.50 (1.2% above fair value)
Industry Position: 32% above the Drug Manufacturers median (#397 of 955)
No single metric tells the full story. See the ASX:VLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vita Life Sciences Ltd is an Australian-based pharmaceutical and healthcare company involved in formulating, packaging, selling, and distributing vitamins and supplements. It produces a wide range of premium supplements, vitamins, minerals, herbs, and superfoods catered to all age categories and health conditions. The company markets its products through pharmacies and health food stores under the VitaHealth, VitaScience, and Herbs of Gold brands throughout the Asia-Pacific region. Vita Life Sciences has two operating segments: VMS Operational, which generates maximum revenue, and VMS Investments. Geographically, the Group generates maximum revenue from Malaysia and Singapore, and the rest from Australia, and China and Vietnam.
94GF Score
Get the complete analysis for ASX:VLS
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VLS has been successfully added to your 
